Oppenheimer Asset Management Inc. decreased its position in Aimmune Therapeutics Inc (NASDAQ:AIMT) by 13.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,958 shares of the biotechnology company’s stock after selling 1,107 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Aimmune Therapeutics were worth $145,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in AIMT. Aperio Group LLC bought a new position in Aimmune Therapeutics during the 2nd quarter valued at about $76,000. Botty Investors LLC bought a new position in Aimmune Therapeutics during the 1st quarter valued at about $2,505,000. DekaBank Deutsche Girozentrale lifted its stake in Aimmune Therapeutics by 21.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,100 shares of the biotechnology company’s stock valued at $423,000 after acquiring an additional 2,700 shares during the period. GSA Capital Partners LLP bought a new position in Aimmune Therapeutics during the 2nd quarter valued at about $221,000. Finally, Manchester Capital Management LLC bought a new position in Aimmune Therapeutics during the 1st quarter valued at about $27,000. Institutional investors own 78.06% of the company’s stock.
Shares of NASDAQ:AIMT traded down $0.79 during trading on Friday, hitting $24.67. The company’s stock had a trading volume of 2,402,300 shares, compared to its average volume of 924,031. The company has a 50-day moving average of $20.08 and a 200-day moving average of $20.80. Aimmune Therapeutics Inc has a 12 month low of $16.95 and a 12 month high of $36.12. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.80 and a quick ratio of 5.80.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.08). During the same period in the previous year, the company posted ($0.91) EPS. Equities research analysts expect that Aimmune Therapeutics Inc will post -4 EPS for the current year.
AIMT has been the topic of several research analyst reports. Zacks Investment Research cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 5th. Credit Suisse Group initiated coverage on shares of Aimmune Therapeutics in a research note on Tuesday, May 21st. They set an “outperform” rating and a $30.00 target price on the stock. BidaskClub cut shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 24th. Royal Bank of Canada lowered their target price on shares of Aimmune Therapeutics to $50.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, Roth Capital initiated coverage on shares of Aimmune Therapeutics in a research note on Friday, July 12th. They set a “buy” rating and a $45.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $41.38.
Aimmune Therapeutics Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Featured Story: How are institutional investors different from individual investors?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.